CFGS
PDLI

Concourse Financial Group Securities’s PDL BioPharma, Inc. PDLI Stock Holding History

Concourse Financial Group Securities’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-12
Closed -$32 – 2306
2019
Q2 		$0 Hold
12
– – ﹤0.01% 2492
2019
Q1 		$0 Hold
12
– – ﹤0.01% 2506
2018
Q4 		$0 Buy
+12
New +$33 ﹤0.01% 2308

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Concourse Financial Group Securities's PDLI Position: Q3 2019 in Review

Concourse Financial Group Securities sold out of PDL BioPharma, Inc. (PDLI) in Q3 2019, closing a stake of 12 shares — an estimated $32 sold.

Concourse Financial Group Securities first reported a position in PDLI in Q4 2018 and held it in 3 quarters. The position peaked at $0 in Q2 2019. 140 funds tracked by Wall St. Rank hold PDLI as of Q3 2019.

  • Concourse Financial Group Securities reported no remaining PDL BioPharma, Inc. position as of Q3 2019 after selling out during the quarter.
  • Concourse Financial Group Securities sold 12 PDL BioPharma, Inc. shares in Q3 2019, an estimated $32.
  • Concourse Financial Group Securities first reported a position in PDL BioPharma, Inc. in Q4 2018 and held it in 3 quarters.
  • Concourse Financial Group Securities's PDL BioPharma, Inc. position peaked at $0 in Q2 2019.
  • 140 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2019.

Based on Concourse Financial Group Securities's 13F filing for Q3 2019, filed 13 Nov 2019.